GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Korea Arlico Pharm Co Ltd (XKRX:260660) » Definitions » Price-to-Owner-Earnings

Korea Arlico Pharm Co (XKRX:260660) Price-to-Owner-Earnings : (As of Jun. 02, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Korea Arlico Pharm Co Price-to-Owner-Earnings?

As of today (2025-06-02), Korea Arlico Pharm Co's share price is ₩4310.00. Korea Arlico Pharm Co does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Korea Arlico Pharm Co's Price-to-Owner-Earnings or its related term are showing as below:

During the past 10 years, the highest Price-to-Owner-Earnings of Korea Arlico Pharm Co was 281.51. The lowest was 14.19. And the median was 177.64.


XKRX:260660's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 25.185
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-06-02), Korea Arlico Pharm Co's share price is ₩4310.00. Korea Arlico Pharm Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was ₩-205.00. Therefore, Korea Arlico Pharm Co's PE Ratio (TTM) for today is At Loss.

As of today (2025-06-02), Korea Arlico Pharm Co's share price is ₩4310.00. Korea Arlico Pharm Co's EPS without NRI for the trailing twelve months (TTM) ended in was ₩-205.00. Therefore, Korea Arlico Pharm Co's PE Ratio without NRI for today is At Loss.

During the past 10 years, Korea Arlico Pharm Co's highest PE Ratio without NRI was 205.52. The lowest was 0.00. And the median was 16.10.


Korea Arlico Pharm Co Price-to-Owner-Earnings Historical Data

The historical data trend for Korea Arlico Pharm Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Korea Arlico Pharm Co Price-to-Owner-Earnings Chart

Korea Arlico Pharm Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 43.02 - - -

Korea Arlico Pharm Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Korea Arlico Pharm Co's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Korea Arlico Pharm Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Korea Arlico Pharm Co's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Korea Arlico Pharm Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Korea Arlico Pharm Co's Price-to-Owner-Earnings falls into.


;
;

Korea Arlico Pharm Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Korea Arlico Pharm Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=4310.00/-1509.66
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Korea Arlico Pharm Co  (XKRX:260660) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Korea Arlico Pharm Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Korea Arlico Pharm Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Korea Arlico Pharm Co Business Description

Traded in Other Exchanges
N/A
Address
7-21, Baumoe-ro 27-gil, Seocho-gu, Seoul, KOR
Korea Arlico Pharm Co Ltd is engaged in the business of manufacturing and selling pharmaceuticals products. The company offers products in the area of the circulatory system, antiplatelet, muscle relaxants, diabetes, antibiotic and chemotherapy, allergy and respiratory disease, ointment, vitamin and health supplements, digestive system, and metabolic disease. It provides products in various forms such as tablets, capsules, gel, and cream.

Korea Arlico Pharm Co Headlines

No Headlines